As an oral small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), apatinib has been demonstrated the efficiency and safety in breast and gastric cancer therapy[9–11]. This evidence concerns the gene KDR and gastric cancer.